* Immunovant Inc IMVT.OQ reported a quarterly adjusted
loss
of 35 cents per share for the quarter ended in June. The mean
expectation of eight analysts for the quarter was for a loss
of 40 cents per share.
* Reported revenue was zero; analysts expected zero.
* Immunovant Inc's reported EPS for the quarter was a loss
of 35
cents.
* The mean earnings estimate of analysts had risen by
about 4.1%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Immunovant Inc shares had risen by 22.1% this quarter and
lost 44.1% so far this year.
* The company reported a quarterly loss of $40.37 million.
* Wall Street's median 12-month price target for Immunovant
Inc is
$12.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 8
at 12:01 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.40 -0.35 Beat
Mar. 31 2022 -0.38 -0.41 Missed
Dec. 31 2021 -0.33 -0.36 Missed
Sep. 30 2021 -0.28 -0.35 Missed